Aripiprazole

BNF:
4.2.1
Status:
Red, Green - after consultant/specialist initiation
Decision Date:
None
 

Comments

GREEN after consultant/specialist initiation:

  • Oral preparation for treating psychosis, bipolar disorder (NICE CG185), depression.  (Decision date - October 2022) 

RED: 

  • NICE TA292: for treating moderate to severe manic episodes in adolescents with bipolar I disorder.  (Oral preparation).  (Decision date - August 2013)
  • Injection (7.5mg) & depot injection (400mg).


MHRA (Dec 2023) Aripiprazole (Abilify and generic brands): risk of pathological gambling - be alert to the risk of addictive gambling and other impulse control disorders. Advise patients and their caregivers to be alert to the development of new or increased urges to gamble and other impulse control symptoms, such as excessive eating or spending, or an abnormally high sex drive. Consider dose reduction or stopping the medication if a patient develops these symptoms. 


Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app